Reports

Sale

Graft Versus Host Disease (GvHD) Treatment Market

Global Graft versus Host Disease (GvHD) Treatment Market: By Type: Acute Graft Versus Host Disease (aGvHD), Chronic Graft Versus Host Disease (cGvHD); By Treatment: mTOR Inhibitors, TNFα Inhibitors, Others; By Distribution Channels; Regional Analysis; Competitive Landscape: Industry Events and Developments; 2024-2032

Global Graft Versus Host Disease Treatment Market Outlook

The global graft versus host disease treatment market size is expected to grow in the forecast period of 2024-2032 at a CAGR of 8.50%.

 

graft versus host disease treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Prevalence of cGvHD is Driving the Global Graft Versus Host Disease Treatment Industry

A significant portion of adults and children surviving for more than 100 days after transplants are affected by chronic graft versus host disease (cGvHD), which is propelling the demand for immunosuppressive medications from healthcare units. The cGvHD can be lethal and the patients requires great care in order to survive. 

 

Moreover, cGvHD can appear after few days, or after several years post-transplant. It might occur in skin, liver, mouth, or lungs, and the symptoms are usually vague. Hence, over the forecast period, the anticipated increase in advancements in healthcare units to improve the diagnosis of this illness is likely to aid the graft versus host disease treatment market growth in the coming years. 

 

North America Holds a Substantial Share in the Market for Graft Versus Host Disease Treatment

The United States is the highest spender on healthcare all over the world. Over the forecast period, the increasing healthcare awareness and stringent government regulations aimed towards bolstering the medical facilities to augment cell therapy and cancer treatment are likely to propel the market growth. In addition to this, the growing geriatric population and increasing prevalence of lifestyle related issues such as obesity, are anticipated to accelerate the market growth in the region.

 

Market Segmentation

 

graft versus host disease treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Graft versus host disease refers to a complication pertaining to allogeneic stem cell transplantation in which the body of a human treats the donated stem cells as foreign objects leading to an attack against them. It is a potentially serious disease which is usually caused due to the significant differences in the body of the host and the donor and requires treatment. 

 

Based on type, the market can be segmented into:

  • Acute Graft Versus Host Disease (aGvHD)
  • Chronic Graft Versus Host Disease (cGvHD)

 

By treatment, the graft versus host disease treatment market has been divided into:

  • mTOR Inhibitors 
  • TNFα Inhibitors
  • SOT Therapies 
  • Corticosteroids
  • Stem Cell Treatments
  • Others

 

The significant distribution channels included in the market are as follows:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

graft versus host disease treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Frequency of Allogeneic Transplantations to Boost the Growth of the Graft Versus Host Disease Treatment Industry

The rising frequency of allogeneic transplantations among adults and geriatrics is leading to an escalation of graft versus host disease. Over the forecast period, the anticipated increase in the cases of blood cancers such as leukaemia and lymphoma are likely to propel the risk of graft versus host disease. This will foster the need for an efficient treatment plan to counter it. 

 

Meanwhile, the emerging online-pharmacies are proving to be a boon for the graft versus host disease treatment market by providing comfort of door-step-delivery to the patients. Over the forecast period, the anticipated increase in research and development activities by the major pharmaceutical and biopharmaceutical industries are likely to lead to progressive product innovations, thereby, navigating the market growth in a positive direction. 

 

The increasing number of players in the field of medical research, coupled with the favourable policies of the government of the emerging economies are likely to provide impetus to the market in the coming years. 

 

Key Players in the Global Market for Graft Versus Host Disease Treatment

The report gives a detailed analysis of the following key players in the global graft versus host disease treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

 

  • Incyte Corporation
  • Sanofi
  • Mesoblast Ltd
  • AbbVie Inc.
  • Bristol Myers Squibb
  • Others

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter’s five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Treatment
  • Distribution Channels
  • Region
Breakup by Type
  • Acute Graft Versus Host Disease (aGvHD)
  • Chronic Graft Versus Host Disease (cGvHD)
Breakup by Treatment
  • mTOR Inhibitors 
  • TNFα Inhibitors
  • SOT Therapies 
  • Corticosteroids
  • Stem Cell Treatments
  • Others
Breakup by Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Incyte Corporation
  • Sanofi
  • Mesoblast Ltd
  • AbbVie Inc.
  • Bristol Myers Squibb
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface 
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions   
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments  
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Region
7    Opportunities and Challenges in the Market  
8    Global Graft Versus Host Disease (GvHD) Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Graft versus Host Disease (GvHD) Treatment Historical Market (2018-2023) 
    8.3    Global Graft Versus Host Disease (GvHD) Treatment Market Forecast (2024-2032)
    8.4    Global Graft Versus Host Disease (GvHD) Treatment Market by Type
        8.4.1    Acute Graft Versus Host Disease (aGvHD)
            8.4.1.1    Historical Trend (2018-2023)
            8.4.1.2    Forecast Trend (2024-2032)
        8.4.2    Chronic Graft Versus Host Disease (cGvHD)
            8.4.2.1    Historical Trend (2018-2023)
            8.4.2.2    Forecast Trend (2024-2032)
    8.5    Global Graft Versus Host Disease (GvHD) Treatment Market by Treatment
        8.5.1    mTOR Inhibitors 
            8.5.1.1    Historical Trend (2018-2023)
            8.5.1.2    Forecast Trend (2024-2032)
        8.5.2    TNFα Inhibitors
            8.5.2.1    Historical Trend (2018-2023)
            8.5.2.2    Forecast Trend (2024-2032)
        8.5.3    SOT Therapies 
            8.5.3.1    Historical Trend (2018-2023)
            8.5.3.2    Forecast Trend (2024-2032)
        8.5.4    Corticosteroids
            8.5.4.1    Historical Trend (2018-2023)
            8.5.4.2    Forecast Trend (2024-2032)
        8.5.5    Stem Cell Treatments
            8.5.5.1    Historical Trend (2018-2023)
            8.5.5.2    Forecast Trend (2024-2032)
        8.5.6    Others
    8.6    Global Graft Versus Host Disease (GvHD) Treatment Market by Distribution Channels
        8.6.1    Hospital Pharmacies
            8.6.1.1    Historical Trend (2018-2023)
            8.6.1.2    Forecast Trend (2024-2032)
        8.6.2    Retail Pharmacies
            8.6.2.1    Historical Trend (2018-2023)
            8.6.2.2    Forecast Trend (2024-2032)
        8.6.3    Online Pharmacies
            8.6.3.1    Historical Trend (2018-2023)
            8.6.3.2    Forecast Trend (2024-2032)
    8.7    Global Graft Versus Host Disease (GvHD) Treatment Market by Region       
        8.7.1    North America
            8.7.1.1    Historical Trend (2018-2023) 
            8.7.1.2    Forecast Trend (2024-2032)
        8.7.2    Europe
            8.7.2.1    Historical Trend (2018-2023) 
            8.7.2.2    Forecast Trend (2024-2032)
        8.7.3    Asia Pacific
            8.7.3.1    Historical Trend (2018-2023) 
            8.7.3.2    Forecast Trend (2024-2032)
        8.7.4    Latin America
            8.7.4.1    Historical Trend (2018-2023) 
            8.7.4.2    Forecast Trend (2024-2032)
        8.7.5    Middle East and Africa
            8.7.5.1    Historical Trend (2018-2023) 
            8.7.5.2    Forecast Trend (2024-2032)
9    North America Graft Versus Host Disease (GvHD) Treatment Market Analysis
    9.1    United States of America 
        9.1.1    Historical Trend (2018-2023) 
        9.1.2    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Historical Trend (2018-2023) 
        9.2.2    Forecast Trend (2024-2032)
10    Europe Graft Versus Host Disease (GvHD) Treatment Market Analysis
    10.1    United Kingdom
        10.1.1    Historical Trend (2018-2023) 
        10.1.2    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Historical Trend (2018-2023) 
        10.2.2    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Historical Trend (2018-2023) 
        10.3.2    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Historical Trend (2018-2023) 
        10.4.2    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Graft Versus Host Disease (GvHD) Treatment Market Analysis
    11.1    China
        11.1.1    Historical Trend (2018-2023)  
        11.1.2    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Historical Trend (2018-2023) 
        11.2.2    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Historical Trend (2018-2023) 
        11.3.2    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Historical Trend (2018-2023) 
        11.4.2    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Historical Trend (2018-2023) 
        11.5.2    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Graft Versus Host Disease (GvHD) Treatment Market Analysis
    12.1    Brazil
        12.1.1    Historical Trend (2018-2023) 
        12.1.2    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Historical Trend (2018-2023) 
        12.2.2    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Historical Trend (2018-2023) 
        12.3.2    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East and Africa Graft Versus Host Disease (GvHD) Treatment Market Analysis
    13.1    Saudi Arabia
        13.1.1    Historical Trend (2018-2023) 
        13.1.2    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Historical Trend (2018-2023) 
        13.2.2    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Historical Trend (2018-2023) 
        13.3.2    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Historical Trend (2018-2023) 
        13.4.2    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Competitive Landscape
    15.1    Market Structure
    15.2    Company Profiles
        15.2.1    Incyte Corporation
            15.2.1.1    Company Overview
            15.2.1.2    Product Portfolio
            15.2.1.3    Demographic Reach and Achievements
            15.2.1.4    Certifications
        15.2.2    Sanofi
            15.2.2.1    Company Overview
            15.2.2.2    Product Portfolio
            15.2.2.3    Demographic Reach and Achievements
            15.2.2.4    Certifications
        15.2.3    Mesoblast Ltd
            15.2.3.1    Company Overview
            15.2.3.2    Product Portfolio
            15.2.3.3    Demographic Reach and Achievements
            15.2.3.4    Certifications
        15.2.4     AbbVie Inc.
            15.2.4.1    Company Overview
            15.2.4.2    Product Portfolio
            15.2.4.3    Demographic Reach and Achievements
            15.2.4.4    Certifications
        15.2.5    Bristol Myers Squibb
            15.2.5.1    Company Overview
            15.2.5.2    Product Portfolio
            15.2.5.3    Demographic Reach and Achievements
            15.2.5.4    Certifications
        15.2.7    Others
16    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Graft Versus Host Disease (GvHD) Treatment Market: Key Industry Highlights, 2018 and 2032
2.    Global Graft Versus Host Disease (GvHD) Treatment Historical Market: Breakup by Type (USD Million), 2018-2023
3.    Global Graft Versus Host Disease (GvHD) Treatment Market Forecast: Breakup by Type (USD Million), 2024-2032
4.    Global Graft versus Host Disease (GvHD) Treatment Historical Market: Breakup by Treatment (USD Million), 2018-2023
5.    Global Graft Versus Host Disease (GvHD) Treatment Market Forecast: Breakup by Treatment (USD Million), 2024-2032
6.    Global Graft versus Host Disease (GvHD) Treatment Historical Market: Breakup by Distribution Channels (USD Million), 2018-2023
7.    Global Graft Versus Host Disease (GvHD) Treatment Market Forecast: Breakup by Distribution Channels (USD Million), 2024-2032
8.    Global Graft versus Host Disease (GvHD) Treatment Historical Market: Breakup by Region (USD Million), 2018-2023
9.    Global Graft Versus Host Disease (GvHD) Treatment Market Forecast: Breakup by Region (USD Million), 2024-2032
10.    North America Graft versus Host Disease (GvHD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
11.    North America Graft Versus Host Disease (GvHD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Europe Graft versus Host Disease (GvHD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
13.    Europe Graft Versus Host Disease (GvHD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Asia Pacific Graft versus Host Disease (GvHD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Asia Pacific Graft Versus Host Disease (GvHD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Latin America Graft versus Host Disease (GvHD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
17.    Latin America Graft Versus Host Disease (GvHD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
18.    Middle East and Africa Graft versus Host Disease (GvHD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
19.    Middle East and Africa Graft Versus Host Disease (GvHD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
20.    Global Graft Versus Host Disease (GvHD) Treatment Market Structure.

Key Questions Answered in the Report

The market is estimated to grow at a CAGR of 3.50% between 2024 and 2032.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major drivers of the market include the increasing prevalence of allogeneic transplantations, rising cases of blood cancer, and increasing healthcare awareness. 

The thriving online-pharmacies is likely to be a key trend in the market.

Acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD) are the different types based on which the market has been divided.

The segments of market based on treatment are mTOR inhibitors, TNFα inhibitors, SOT therapies, corticosteroids, and stem cell treatments, among others.

Hospital pharmacies, retail pharmacies, and online pharmacies are the significant distribution channels included in the market report. 

The major players in the industry are Incyte Corporation, Sanofi, Mesoblast Ltd, AbbVie Inc., and Bristol Myers Squibb, among others. 

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER